MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date

Thursday, June 23, 2016

12:00pm-1:30pm
The Luxembourg Parkinson’s study: Integrating the Lewy body composite risk score into a longitudinal study

M. Kerschenmeyer, P. Kolber, G. Hipp, K. Roomp, S.K. Mosch, A. Schweicher, L. Longhino, M. Falz, V.P. Satagopam, M. Gantenbein, M. Vaillant, F. Betsou, A. Chioti, R. Schreiner, R. Krüger (Belval, Luxembourg)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The neurosteroid dehydroepiandrosterone sulfate (DHEAS) reverses the dopaminergic deficiencies in mild hepatic encephalopathy: A possible therapeutic issue for the management of parkinsonism in cirrhotic patients

O. El Hiba, H. Gamrani (Marrakesh, Morocco)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The NIC-PD-study –Baseline data of a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson’s disease in Germany and the USA

W.H. Oertel, C. Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, H. Mueller, M.M. Unger, K.M. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination

J. Ellmen, J. Tuunainen, A. Holopainen, T. Sarapohja, M. Scheinin (Turku, Finland)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The Parkinson progression marker initiative (PPMI) – Developing a comprehensive longitudinal biomarker dataset

Parkinson Progression Marker Initiative (New Haven, CT, USA)

Parkinsons's Disease: Clinical Trials I
12:00pm-1:30pm
The potential therapeutic effect of intranasal administration of stem cells in rotenone model of Parkinson’s disease in mice

M. El-Gamal, M. Salama, M. Sobh, M. Emam, A. Abdalla, A. Lotfy, D. Sabry, M. El-Qotb, M. Sobh (Mansoura, Egypt)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The prevalence of non- motor symptoms in dystonia

P.M. de Carvalho Aguiar, F.P. da Silva-Junior, S.M. Azevedo Silva, E.R. Barbosa, V. Borges, M.S.G. Rocha, J.C.P. Limongi, H.B. Ferraz (Sao Paulo, Brazil)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The role and underlying mechanisms of BAG3 in regulating autophagy in PC12 cells

Y.P. Yang, Y.L. Cao, C.J. Mao, F. Wang, L.F. Hu, C.F. Liu (Suzhou, People's Republic of China)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The role of acoustic salience in acoustic cueing and sound-based motor rehabilitation

B.G. Schultz, S.A. Kotz (Maastricht, Netherlands)

Other  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
The role of active rehabilitation measures, for maintaining the quality of life of patients after stroke with movement disorders in the general practice conditions

G. Sadullaeva (Tashkent, Uzbekistan)

Other  ·  Exhibit Hall located in Hall B, Level 2